Previous 10 | Next 10 |
home / stock / entbf / entbf news
Vancouver, British Columbia--(Newsfile Corp. - January 6, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personali...
Subsidiary HaluGen Life Sciences has expanded its genetic test panel to include the CYP2D6 gene, a marker indicating the metabolism of LSD, MDMA and ayahuasca Vancouver, British Columbia--(Newsfile Corp. - December 21, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ( ...
Vancouver, British Columbia--(Newsfile Corp. - December 16, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide persona...
Entheon Biomedical (CSE: ENBI) (OTCQB: ENTBF) is researching and developing psychedelic drugs for the treatment of addiction disorders. With a focus on the psychedelic DMT molecule, Entheon’s upcoming trial, EBRX-101 is designed to be one of the most comprehensive studies of DMT to ...
Toronto, Ontario--(Newsfile Corp. - December 3, 2021) - Eric Sprott announces that, today, 600,000 common share purchase warrants (Warrants) of Entheon Biomedical Corp., (held by 2176423 Ontario Ltd., a corporation he beneficially owns) expired unexercised representing a decrease in holdings o...
Vancouver, British Columbia--(Newsfile Corp. - December 3, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personal...
Detroit, Michigan--(Newsfile Corp. - December 3, 2021) - Entheon Biomedical (CSE: ENBI) will be presenting at the Benzinga Global Small Cap Conference taking place on December 8-9, 2021. We invite our shareholders and all interested parties to explore investment opportunities within the gl...
Vancouver, British Columbia--(Newsfile Corp. - December 1, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personal...
Shipment of GMP DMT, In Vitro HERG and Genotox Assays Completed, and In Vivo Toxicity Assays Underway Vancouver, British Columbia--(Newsfile Corp. - November 24, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biotechnology company f...
Entheon Biomedical (OTCQB:ENTBF) announces that recruitment has begun for the clinical research study with Heading Health to determine the electro-neurophysiologic effects of ketamine. EBIQ-101, an Open Label Observational Study, will observe the EEG pattern of participants being treated...
News, Short Squeeze, Breakout and More Instantly...
Entheon Biomedical Corp Com Company Name:
ENTBF Stock Symbol:
OTCMKTS Market:
Entheon Biomedical Corp Com Website:
2024-03-27 17:08:02 ET Addiction is an issue that affects a significant number of people worldwide. While conventional treatments have existed for decades, they offer a very low rate of efficacy, often as low as 5%. For Timothy Ko , CEO of Entheon Biomedical , the problem ...
2024-03-27 17:08:02 ET Leading-edge addiction recovery solution Entheon Biomedical is pioneering a leading-edge addiction recovery solution that harnesses the therapeutic potential of patient-centric psychedelic medicine to remedy the underlying causes of Substance Use Disorde...
MIAMI, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”) , a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, today issued a letter to shareholders from its Chief Executive Officer, Ben Kaplan. Dear Fel...